Skip to Content
Merck
CN
  • Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent.

Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent.

Circulation. Cardiovascular interventions (2021-03-02)
Ajay J Kirtane, Robert Stoler, Robert Feldman, Franz-Josef Neumann, Loukas Boutis, Naeem Tahirkheli, Ralph Toelg, Islam Othman, Bernardo Stein, James W Choi, Stephan Windecker, Robert W Yeh, Harold L Dauerman, Matthew J Price, Paul Underwood, Dominic Allocco, Ian Meredith, Dean J Kereiakes
ABSTRACT

[Figure: see text].

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Suplatast tosylate, ≥98% (HPLC)
Sigma-Aldrich
DAPT, ≥98% (HPLC), solid